Monday, February 23, 2015
Bina Technologies, the genomic big data science company accelerating personalized medicine, has expanded its advisory board and commercial team. This announcement marks the latest in the company’s initiatives to significantly improve genomics data analysis workflows used in clinical research. Bina has expanded its scientific advisory board (SAB), adding four luminaries with experience in clinical genomics research. The company also has brought on two commercial team leaders, tapping into their combined 40+ years of experience driving revolutionary technologies into the genomics market.
Rigel Pharmaceuticals plans to focus resources on the completion of three lead clinical programs. These efforts include a phase III clinical study of fostamatinib, an oral SYK inhibitor, in Immune Thrombocytopenic Purpura (ITP), pending discussions with regulatory agencies. Rigel believes that a phase III clinical program would encompass approximately 150 patients and can be completed in 2015.
Biopharmaceutical companies AstraZeneca and Rigel Pharmaceuticals have signed an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel’s inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signaling being investigated as a treatment for moderate to severe chronic asthma.
Rigel Pharmaceuticals will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several phase I clinical trials. Pfizer is returning full rights to the R343 program as a result of its decision to exit the allergy and respiratory therapeutic area within R&D. Rigel is evaluating the details of R343’s development to date and expects to design a phase II clinical trial with R343 later this year.